PremiumCompany AnnouncementsMersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges Mersana Therapeutics Reports Progress and Financial Results Mersana Therapeutics’ Earnings Call Highlights Clinical Progress and Financial Gains PremiumPre-EarningsMRSN Upcoming Earnings Report: What to Expect? Mersana Therapeutics initiated with an Outperform at William Blair Mersana Therapeutics initiated with an Outperform at William Blair PremiumThe FlyMersana Therapeutics: FDA grants additional Fast Track designation to XMT-1660 Mersana Therapeutics: ‘Positive’ results from Phase 1 emiltatug ledadotin trial Mersana Therapeutics transferred with Buy rating at Citi 
